Abdominal aortic aneurysms are relatively common and often life-threatening, with especially high mortality after aneurysm rupture. The introduction of endovascular aneurysm repair, a minimally invasive alternative to traditional open repair, led to decreased mortality and morbidity in randomized controlled trials, but these trials were conducted in highly selected patients and providers and were underpowered to detect differences in rare adverse events throughout follow-up. With observational studies of Medicare beneficiaries, we demonstrate that the randomized trial results are generalizable to the majority of patients undergoing abdominal aortic aneurysm repair in the United States. Additionally, with a larger cohort, comparative analyses evaluating rare, previously unstudied late outcomes such as laparotomy-related complications, late reinterventions, mortality with reinterventions, and late rupture could be conducted. Furthermore, trends in management over time and relationships between surgeon and hospital volume and outcomes can be studied. The goal of this review was to summarize the existing literature regarding abdominal aortic aneurysms among Medicare beneficiaries and to evaluate the benefits and limitations of administrative claims data in comparative effectiveness research. (Surgery 2017;162:721-31.) From the Beth Israel
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From the Beth Israel Deaconess Medical Center, Boston, MA ABDOMINAL AORTIC ANEURYSMS (AAA) are relatively common and often life-threatening, with over 15,000 domestic AAA ruptures annually and a mortality of >80% with aneurysm rupture.
1-3 AAA were first described in the 16th century by the French anatomist Vesalius 4 ; however, over 3 centuries passed before the first successful repair was performed. While many surgeons attempted to treat AAA with aortic ligation, Rudolph Matas in 1923 was the first to do this successfully, and the patient subsequently lived 18 months. 5 By 1940, however, only 23 ligations had been recorded and only 5 of these were successful. 6 Later, cellophane was used to wrap the aorta in an attempt to restrict growth that, infamously, failed to prevent the death of Albert Einstein.
Major advances were then rapidly made when Dubost et al 7 performed the first successful homograft replacement in 1951, Voorhees et al 8 implanted the first successful prosthetic aortic graft into a dog in 1952, and DeBakey and Cooley 9 completed the first thoracic aortic replacement with Dacron in 1953. Finally, in 1966, Creech combined the prosthetic graft technique with the endoaneurysmorrhaphy described by Matas in 1903, 10 leading to the modern open AAA repair.
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With the success of this procedure, surgeons began to electively repair aortic aneurysms to prevent rupture and its accompanying mortality and morbidity. After early advances, however, little progress was made as rates of elective AAA repair, of ruptured AAA (rAAA), and mortality with elective and rAAA remained stable from the late 1970s to 1990s. 12 The introduction of endovascular aneurysm repair (EVAR), a minimally invasive alternative to traditional open repair, in 1991 by Dr Juan Parodi, however, revolutionized aneurysm management. The Food and Drug Administration approved EVAR in 1999, and now 80% of infrarenal aneurysm repairs are performed endovascularly, allowing patients previously considered too high risk for open surgery to undergo repair.
In the 2000s, three major randomized, controlled trials (RCTs), the United Kingdom EndoVascular Aneurysm Repair (EVAR-1), 13 Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group, 14 and Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group, 15 showed that EVAR has lower perioperative mortality and morbidity compared to open repair. A meta-analysis of randomized trials showed a significant mortality benefit with 1.4% mortality after EVAR and 4.2% after open repair in 2,790 total patients. These randomized trials, however, were limited by including only highly selected subjects amenable medically and anatomically to both open and endovascular repair and were conducted only in highly selected institutions with experienced physicians. Therefore, the generalizability of these results to the average American population may be limited. Furthermore, with fewer than 3,000 patients combined, the studies were underpowered to detect differences in rare and remote outcomes, such as late reintervention, laparotomy-related complications, and rupture.
The Medicare Program from the Center for Medicare and Medicaid Services (CMS) is uniquely positioned to address the limitations of these randomized trials. Medicare is the United States' health insurance program for adults aged 65 years and older, some persons under age 65 years with disabilities, and persons with specified chronic medical conditions, such as end-stage renal disease. Approximately 97% of persons aged 65 years and older are covered by Medicare. All claims files are generated annually and can be used to construct patient-level longitudinal histories of health care utilization for Medicare beneficiaries enrolled in traditional fee-for-service (FFS) Medicare. While CMS collects and maintains health care claims for all services billed to and paid for under Medicare's FFS payment system, they do not have claims data available for research for those enrolled in Medicare Advantage, Medicare's managed care program, which made up 5% to 10% of Medicare beneficiaries between 2001 and 2008. 16 As 70% of the AAA repairs performed in the United States are covered by FFS Medicare, these data are widely generalizable across the country. Additionally, with over 15,000 beneficiaries undergoing elective AAA repair per year, we are much better powered using observational Medicare data than the randomized trials to detect differences in late outcomes. Furthermore, with Medicare, we can better address questions about the durability of EVAR and differences by graft type and account for prior laparotomy in propensity score models.
The goal of this review was to summarize our existing studies of abdominal aortic aneurysms among Medicare beneficiaries and to evaluate the benefits and limitations of administrative claims data in comparative effectiveness research.
MEDICARE CLAIMS DATA
We used data from several CMS sources: (1) 
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For studies involving comparative analyses or risk prediction modeling, we limited our analysis to patients aged 67 or older at the time of repair, as this allowed us to obtain 2 years of data prior to the procedure for purposes of controlling for baseline health status and clinical conditions. We used inpatient and outpatient ICD-9 diagnosis codes throughout those 2 years, not including the index admission, to determine preoperative comorbidities for each patient. Then, using a method adapted from the Elixhauser algorithm to include outpatient diagnoses, 17, 18 we matched each beneficiary who underwent endovascular repair to the beneficiary who underwent open repair with the closest estimated propensity score.
In the unmatched cohort, EVAR patients were older and sicker, with higher rates of essentially all comorbid conditions; however, after propensityscore matching, there were no statistical differences between EVAR and open repair patients. 19, 20 By propensity score matching on demographics and comorbid baseline conditions, we could control for the nonrandom assignment of patients to 1 of the 2 procedures.
PERIOPERATIVE MORTALITY
In our initial comparative effectiveness studies among Medicare beneficiaries, we used the above methodology to identify all patients aged 67 or older with at least 2 years of claims data who underwent open or endovascular repair of intact AAA between 2001 and 2004. We identified 45,660 propensity-score matched beneficiaries, with half of these undergoing open and the other half endovascular repair. 20 We found that combined 30-day and in-hospital mortality was 5.3% after open repair but only 1.7% after endovascular repair (relative risk for the open repair group 3.2, 95% confidence interval [CI] 2.8-3.5, P < .001). 20, 21 These results are comparable to those found in a meta-analysis of RCTs, despite including a more generalized cohort. 22 The most significant mortality discrepancy was in patients older than 85, with an absolute 30-day and in-hospital mortality difference of 8.5%, suggesting that these older patients most benefited by the introduction of EVAR. 20 We performed a subsequent analysis with Medicare beneficiaries from 2001-2008, with 79,932 propensity-matched patients. The perioperative mortality remained significantly higher after open repair (5.2% vs 1.6%, P < .001). Notably, however, the rates of both decreased steadily over the 8-year period, with an 11% reduction in mortality after open repair (5.7% to 5.1%, P = .001), but a 36% mortality reduction after EVAR (2.2% to 1.4%, P = .01). 19 Notably, the rate of death after open repair did not stabilize until 3 months postoperatively, at which point interval death rates approached that of EVAR (Fig 1) . 21 Additionally, the rate of early conversion to open repair dropped dramatically over the same time period, from 2.2% to 0.3% (P < .001).
MORTALITY RISK PREDICTION MODEL
Using Medicare beneficiaries from 2001-2004, we also developed a risk prediction model for perioperative mortality after AAA repair. 23 We again used propensity-score matched cohorts to conduct this analysis, with half the sample used to develop the prediction model and the other half used to validate the model. We found the strongest predictors of in-hospital or 30-day mortality were open repair (odds ratio [OR] 3.2, 95% CI 2.7-3.8), age >80 years (OR 3.1, 95% CI 2.4-4.2), and end-stage renal disease (OR 2.6, 95% CI 1.5-4.6). Other predictors included age 76 to 80 years (OR 1.9, 95% CI 1.4-2.5), female sex (OR 1.5, 95% CI 1.3-1.8), chronic renal insufficiency (OR 2.0, 95% CI 1.6-2.6), congestive heart failure (OR 1.7, 95% CI 1.5-2.1), and peripheral/cerebral vascular disease (OR 1.3, 95% CI 1.2-1.6). There were no differential interactions between these variables and repair type.
From these results, we developed a scoring system that places patients into high-, medium-, or low-risk categories, with differential mortality rates after open versus endovascular repair (Table I) . 23 This scoring system was validated within the second half of our cohort, with the area under the receiver operative curve of 71.8 in the validation cohort. Most notably, with increased preoperative comorbidity burden, the absolute mortality benefit from EVAR compared to open repair increases, with significantly more favorable outcomes after EVAR.
PERIOPERATIVE MORBIDITY
We also found that perioperative morbidity is significantly lower after EVAR compared to open repair. In our series of patients from 2001-2004, we showed lower rates of myocardial infarction (7.0% vs 9.4%, P < .001), pneumonia (9.3% vs 17%, P < .001), acute renal failure (5.5% vs 11%, P < .001), and dialysis (0.4% vs 0.6%, P < .001) in EVAR patients compared to open repair. 20 although the rates were low in both groups, including acute mesenteric ischemia (2.1% vs 1.0%, P < .001), reintervention for bleeding (1.2% vs 0.8%, P < .001), embolectomy (1.7% vs 1.3%, P < .001), and tracheostomy (1.6% vs 0.2%, P < .001). 20 Abdominal complications were higher in the open repair group: bowel resection (1.3% vs 0.6%, P < .001) and obstruction or ileus without intervention (17% vs 5.1%, P < .001). The hospital length of stay (LOS) was also shorter in the EVAR group, with a mean LOS of 3.4 days vs 9.3 days (P < .001) and median LOS of 2 days vs 7 days (P < .001), and fewer patients were discharged to a skilled nursing facility (5.6% vs 18%, P < .001).
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LATE SURVIVAL
The mid-and long-term outcomes from the 3 major RCTs showed loss of the initial survival benefit of EVAR 1 to 2 (DREAM and EVAR-1) or 5 years (OVER) after repair. [24] [25] [26] In our substantially larger cohort that was not restricted to patients who would qualify medically for a clinical trial, we still identified an early survival advantage among all age groups, which lasted for approximately 3 years. We showed rates of overall survival similar to the rates found in the RCTs, with an 8-year survival of 45.1% after EVAR and 45.3% after open repair (P = .76). Notably, the risk (hazard) of death was not proportional over time (Table II) . 19 Although EVAR was associated with a substantial early survival benefit, rates of death were higher after EVAR between 90 days and 4 years postoperatively among those who had survived to this period, after which the rates remained higher but only slightly (hazard ratio 1.05, 95% CI 1.00-1.09).
The reason for the increased hazard of death after EVAR after 90 days is likely multifold, and chance alone is unlikely given that these findings have been repeated in many series. 15, 19, 24, 26 We believe that the main reason is that the older, sicker patients can survive EVAR but then die sooner than the younger, fitter patients who undergo open repair. Late rupture and reintervention, however, likely also play a role.
LATE OUTCOMES
Reintervention. One of the goals of using Medicare data was to establish a cohort of AAA patients large enough to be powered to detect differences in rare although clinically significant late outcomes. One of the early criticisms of EVAR was the concern for graft durability, with high rates of AAA-related complications. The EVAR-1 study indeed reported significantly lower rates of reintervention-free survival after EVAR at 8 years (72% vs 90%, P < .001). 26 This only accounts for AAA-related complications, however, and the majority of vascular reinterventions after EVAR are relatively minor endovascular procedures.
Not all late complications are graft related. In particular, patients undergoing EVAR will not have a transabdominal or retroperitoneal incision; therefore, laparotomy-related complications should be accounted for, including abdominal wall hernias (with repair) and bowel obstructions (those managed with nonoperative admission as well as those who underwent lysis of adhesion or bowel resection).
In our 8-year follow-up of Medicare beneficiaries, we confirmed that aneurysm-related interventions were much more common after EVAR (19% vs 3.7%, P < .001), including major reinterventions (2.3% vs 0.8%, P < .001), such as conversion to open and graft infection, and minor reinterventions (18% vs 3.1%, P < .001), such as coil embolization or extension (Table III) . Laparotomy-related reinterventions, especially incisional hernia repairs, however, were more common among patients undergoing open repair (18% vs 8.2%, P < .001), as were nonoperative admissions for bowel obstructions (22% vs 17%, P < .001).
After combining aneurysm-related interventions with laparotomy-related interventions, patients undergoing endovascular repair did still have higher rates of reinterventions (25% vs 21% at 8 years, P < .001). 19 Additionally, a large percentage of the reinterventions after EVAR were only "minor" vascular reinterventions. Conversely, hospitalizations related to the aneurysm-or laparotomyrelated complications without intervention were lower after EVAR (18% vs 22%, P < .001).
Interestingly, after stratifying our cohort by age, we found that only patients age 75 years or older were more likely to have reinterventions after EVAR, with patients <75 more likely to have reinterventions after open repair (Table III) . This likely reflects improved patient selection in younger, healthier patients with little perioperative survival difference for whom a more durable repair is desired and an acceptance of higher late reintervention and rupture risk in older, more frail patients in whom the up-front mortality difference is substantial.
Rupture. Another concern with the durability of EVAR is that it will lead to higher rates of late rupture than traditional open repair. As the rates of late rupture are quite low, however, this hypothesis had not previously been demonstrated. In our study of Medicare beneficiaries from 2001-2008, we identified significantly higher rates of rupture after EVAR, with rates of 5.4% after EVAR and 1.4% after open repair through 8 years of followup (P < .001). 19 Overall, we found that patients undergoing EVAR had lower freedom from rupture, aneurysm-related reintervention, and laparotomyrelated reintervention compared to open repair patients (Fig 2) . These curves increasingly separate over time, suggesting that, among patients with long life expectancy, we need to identify those at risk for late reintervention and rupture and consider this in the operative approach.
Mortality with reintervention and rupture. The occurrence of rupture, reintervention, and readmission in follow-up are not insignificant complications. In a separate analysis of Medicare beneficiaries from 2001-2004, we showed that overall rates of readmission or reintervention were slightly higher after EVAR (7.6 vs 7.0/100 person-years, relative risk 1.1, P < .001), with a 30-day mortality of 9.1% associated with reinterventions, notably higher than the mortality associated with the index AAA repairs. 27 Patients undergoing EVAR were more likely to undergo AAA-related interventions (major intervention and minor open minor endovascular AAA-related category, which carried a lower overall 30-day mortality of 4% compared to 13.7% after major AAA-related reinterventions. Major laparotomy-related reinterventions also were associated with a relatively high 30-day mortality of 12.2% and were more than twice as common after open repair. Late AAA rupture, although rare, was again 6 times more likely after EVAR and was associated with a 28% mortality. 27 After exclusion of deaths within 90 days of the original AAA intervention, patients with a reintervention or readmission after EVAR had a decreased survival compared with those without.
Similarly, after open AAA repair, patients who needed a reintervention or readmission had a lower long-term survival. Furthermore, survival among patients who underwent open repair with reintervention was lower than with those who underwent EVAR without reintervention (Fig 3) .
Among patients who never experienced rupture, reintervention, or readmission for laparotomy-related complications, the survival curves meet one year later at 4 years, after which they are overlapping (Fig 4) . Given these findings, the differences in rates of rupture and reintervention alone do not explain the higher hazard of late mortality in patients undergoing EVAR. The patients who survive EVAR are older and sicker and therefore more likely to die early than the healthier patients who survive open repair.
TRENDS IN AAA PRESENTATION, REPAIR, AND MORTALITY
Medicare claims data are uniquely situated to be able to show near-complete population-level data for patients over the age of 65 years in the United States. While unable to capture patients who die from AAA rupture prior to hospital presentation, Medicare claims data allow for trend analysis of AAA-related mortality, rates of rupture, and type of repair. We analyzed all Medicare beneficiaries who presented with AAA during the period from 1995 to 2008 and found that while the use of EVAR increased from 1.5% to 77%, more intact AAA repairs were performed (79.9 to 85.0 repairs per 100,000 Medicare beneficiaries) and fewer patients presented with rupture (33.4 to 16.8 ruptures per 100,000 beneficiaries). 28 Those patients aged 80 years and older seemed to derive the most benefit from the introduction of EVAR, with rates of intact AAA repair increasing from 57.7 to 92.3 per 100,000 Medicare beneficiaries, with 83% of these repairs done via EVAR in 2008. Over this time period, overall short-term aneurysm-related mortality, which included perioperative mortality after intact and ruptured repair as well as in-hospital mortality from rAAA without repair, decreased from 26.1 to 12.1 per 100,000 Medicare beneficiaries (Fig 5) .
Therefore, we have shown decreased aneurysmrelated mortality with time as EVAR has become more frequently utilized, with the largest benefit in those patients >80 years old who were likely to have been considered too high risk for open operative repair. Outcomes after EVAR are also improving, as 2-year rates of aneurysm-related reintervention after EVAR have decreased from 10.4% to 9.1% (P < .001), due primarily to lower rates of coil embolization for type II endoleak (4.2% to 2.5%, P < .001).
Overall mortality after rAAA has decreased for the first time in decades to 36.3%, due primarily to the markedly lower mortality of 27.5% after EVAR for rAAA (Fig 6) . If the observed lower mortality with EVAR for rAAA was simply a matter of selection of the more hemodynamically stable patients who would do well with either approach, then one would expect a concomitant increase in open repair mortality over time with a stable overall mortality rate. Instead, the mortality rate with open repair remains stable; thus, these data strongly support the concept that rAAA mortality is in fact lower since the introduction of EVAR.
As EVAR is more frequently used and perioperative outcomes of intact AAA repair improve, increased screening may identify more aneurysms and allow for timely repair. However, currently, US Preventative Services Task Force guidelines only recommend a one-time screening ultrasound in men aged 65 to 75 years with a history of smoking, and these patients, as well as those with a family history of AAA, are the only ones reimbursed by CMS for a screening ultrasound.
Unfortunately, we previously identified that compliance with screening ultrasound attendance is low. We previously contacted 30,000 randomly selected Medicare beneficiaries, not restricted by age or sex, from the referral region of 3 university- affiliated hospitals and found that only 7% of patients contacted actually presented for free screening ultrasound. Among the screened patients, 2.8% of men and 0.2% of women were found to have previously undetected aneurysms, although these estimates are likely lower than the general population, as they reflect the more-well patients who were willing to attend screening. Now that this is a service provided by Medicare for a subgroup of beneficiaries, further studies are necessary to determine the role of expanded screening to additional groups and to consider targets for quality improvement to improve compliance with screening attendance.
VOLUME-OUTCOMES RELATIONSHIP
An additional benefit of using Medicare claims data is the ability to perform volume-outcomes analyses. Multiple series using the Nationwide Inpatient Sample and Medicare have identified relationships between surgeon volume and outcomes after AAA repair. [29] [30] [31] [32] [33] [34] Using Medicare data, we initially evaluated the influence of institutional volume on outcomes using cases from [2001] [2002] [2003] [2004] . 32 During that time period, there was a marked drop in mortality after EVAR between the first and second lowest quintiles of institutional volume, with steady decreases in each subsequent quintile, suggesting that only a very low institutional threshold is necessary with little improvement beyond that low level.
With open repair, however, there were steady decreases in mortality across each increased quintile of volume. However, these data reflect the relatively early experience with EVAR, which has now become much more widely utilized. Furthermore, this study did not account for surgeon volume. Therefore, we conducted an additional analysis of Medicare data from 2001-2008 and found that while perioperative mortality after EVAR was not associated with surgeon volume, it did decrease slightly with greater hospital volume (1.9% in quintile 1 vs 1.4% in quintile 5). 34 After open repair, perioperative mortality decreased independently with both higher surgeon volume (6.4% in quintile 1 vs 3.8% in quintile 5) and hospital volume (6.3% in quintile 1 vs 3.8% in quintile 5). While the specific volumes necessary to achieve acceptable perioperative outcomes are not agreed on, these data suggest that EVAR and open repair should be performed in high-volume centers and that open repair should be performed by highvolume surgeons.
DISCUSSION
Using Medicare claims data, we have previously shown that endovascular AAA repair is associated with lower perioperative mortality and morbidity, with increased rates of long-term reinterventions and rupture and comparable long-term mortality. [19] [20] [21] 23, 27, 28, 35 Perhaps the most important benefit of using Medicare claims data is that we are able to capture a nearly comprehensive sample of patients undergoing AAA intervention in this country because greater than 70% of AAA repairs are conducted under the Medicare program. Our analyses demonstrate that the results of the landmark randomized, controlled trials conducted in centers of excellence are generalizable to the broad US population. 15, 36, 37 Notably, this is not always the case, as Wennberg et al [38] [39] [40] identified higher rates of perioperative mortality after carotid endarterectomy in a cohort of all Medicare beneficiaries than was seen in either the North American Symptomatic Carotid Endarterectomy Trial (NASCET) or Asymptomatic Carotid Artery Study (ACAS) trials. Additionally, we have been able to evaluate much larger cohorts of patients, with adequate power to detect differences in rare, late complications, such as rupture and reintervention by type of procedure. Medicare also provides the unique opportunity to perform analyses of outcomes by hospital and surgeon volume. An additional benefit of Medicare data for future analyses is the ability to link hospital claims and diagnosis codes with costs, including all costs throughout follow-up.
Despite these advantages, Medicare claims data are limited to diagnosis and billing codes. While some clinical granularity can be deduced by the types of procedure codes used, most vascularspecific data, including aneurysm size and other anatomic characteristics, are not available. Furthermore, only patients over the age of 65 years are included, so any analyses on optimal management in patients aged <65 years cannot be performed, although this is a small minority of AAA patients. The large numbers of patients included in Medicare studies and the capability of analyzing comprehensive long-term follow-up data without loss to follow-up to other institutions, however, still makes Medicare uniquely positioned for comparative effectiveness studies. In the future, some of the limitations related to lack of anatomic and clinical granularity will be addressed by linkage of patients in national vascular registries to their Medicare claims data. This will allow for further patient-centered evaluation of the decision to treat with an endovascular or open approach.
In conclusion, among Medicare beneficiaries, endovascular aneurysm repair is associated with decreased perioperative mortality and morbidity compared to open repair. Late complications, such as rupture and reintervention, are more frequent in patients undergoing EVAR and are associated with high rates of periprocedure mortality. The majority of reinterventions after EVAR, however, are minor AAA-related procedures, whereas patients undergoing open repair have higher rates of laparotomy-related complications.
In the future, studies of Medicare beneficiaries would be enhanced by linkage to registries with more detailed clinical and anatomic data to predict who is at risk for late rupture and reintervention in order to best understand which patients would most benefit from endovascular versus open repair.
